Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the importance of intervention in chronic phase myelofibrosis.<br />
Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the importance of intervention in chronic phase myelofibrosis.
Although myelofibrosis is considered a chronic disease, it does not stay chronic forever, says Verstovsek. The average survival for patients with myelofibrosis is 5 to 7 years, but giving ruxolitinib (Jakafi) in the chronic phase for some patients can prolong life. Patients with myelofibrosis are at risk of their disease transforming to acute myeloid leukemia (AML), which has a worse prognosis and limited therapeutic options. Verstovsek says that patients must be monitored for disease transformation carefully, as AML does not develop overnight.
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More
Weighing the Triggers for Initiating JAK2 Inhibition Therapy in MF
March 23rd 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More